Commentaries
Vol. 4 No. 2 (2025)
Comments on “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 1 July 2025
1312
Views
419
Downloads
Authors
Quoting Jake Elwood, after reading the review by May et al., “we’ve seen the light.” Indeed, the term “anticoagulation stewardship” can serve as a programmatic manifesto for every scientific society dealing with hemostasis and thrombosis. The expression “antimicrobial stewardship” has become widely used and integrated into healthcare service planning, so why not start thinking in terms of “anticoagulation stewardship”?.....
Downloads
Download data is not yet available.
Citations
1. May JE, Allen AL, Samuelson Bannow BT, et al. Safe and effective anticoagulation use: case studies in anticoagulation stewardship. J Thromb Haemost 2025;23:779-89. DOI: https://doi.org/10.1016/j.jtha.2024.11.024
2. Budnitz DS, Shehab N, Lovegrove MC, et al. US emergency department visits attributed to medication harms, 2017-2019. JAMA 2021;326:1299-309. DOI: https://doi.org/10.1001/jama.2021.13844
3. Burnett AE, Barnes GD. A call to action for anticoagulation stewardship. Res Pract Thromb Haemost 2022;6:e12757. DOI: https://doi.org/10.1002/rth2.12757
4. Anticoagulation Forum. Core Elements of Anticoagulation Stewardship Programs. Newton, Anticoagulation Forum; 2019.
5. National Quality Forum. Advancing Anticoagulation Stewardship: A Playbook. Washington, DC, National Quality Forum; 2022.
6. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 2016;9:182–5. DOI: https://doi.org/10.1161/CIRCOUTCOMES.115.002366
7. Sylvester KW, Chen A, Lewin A, et al. Optimization of DOAC management services in a centralized anticoagulation clinic. Res Pract Thromb Haemost 2022;6:e12696. DOI: https://doi.org/10.1002/rth2.12696
8. Samuelson Bannow B. Are outpatient anticoagulation management services the wave of the future (again)? Res Pract Thromb Haemost 2022;6:e12735. DOI: https://doi.org/10.1002/rth2.12735
9. Lee J, Lindsley J, Chasler J, et al. The impact of an antithrombotic stewardship program on heparin-induced thrombocytopenia management. J Pharm Pract 2023;36:1343-9. DOI: https://doi.org/10.1177/08971900221116185
10. Rudd K, Winans A, Triller D. Standardizing periprocedural anticoagulation management: a stewardship initiative. J Thromb Thrombolysis 2023;56:361-7. DOI: https://doi.org/10.1007/s11239-023-02854-2
11. Samuelson Bannow BT. Management of abnormal uterine bleeding on anticoagulation: the patient-clinician perspective. J Thromb Haemost 2024;22:1819-25. DOI: https://doi.org/10.1016/j.jtha.2024.04.002
12. National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: assessment and management. National Institute for Health and Care Excellence: Clinical Guidelines. London, NICE; 2021.
13. Silvari V, Crowley E, Carey M, et al. Value of hospital anticoagulation stewardship programme: a systematic review. Thromb Update 2024;14:100158. DOI: https://doi.org/10.1016/j.tru.2023.100158
14. McLintock C, Pabinger I, Bauer KA, et al. International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. J Thromb Haemost 2016;14:3-27. DOI: https://doi.org/10.1111/jth.13162
How to Cite
1.
Marietta M, Castaman G. Comments on “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”. Bleeding Thromb Vascul Biol [Internet]. 2025 Jul. 1 [cited 2025 Nov. 8];4(2). Available from: https://www.btvb.org/btvb/article/view/180
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share
Similar Articles
- Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz, Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- CO39 | Artificial intelligence in hemophilia management: challenging the need for experts , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO29 | Quality of anticoagulation as a predictor of early left ventricular thrombosis resolution: a retrospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Anna Falanga, Hugo Ten Cate, Bianca Rocca, How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Giovanni de Gaetano, Welcome to AICE and sincere wishes for peace for the new year 2024 , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Carlamaria Zoja, Ariela Benigni, Giuseppe Remuzzi, Hemostasis and the kidney: an unforeseen initial opportunity to create a small research group that grew into an institute , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 2 (2025)
- Massimo Franchini, Daniele Focosi, The changing landscape of treatment for acquired hemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- PO83 | A case of deep vein thrombosis in a patient with systemic mastocytosis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno, The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Giancarlo Castaman, Gene transfer in hemophilia B: a big step forward , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Gianfranco De Girolamo, Luca Sarti, Sonia Cecoli, Karin Bonora, Chiara Ajolfi, Francesco Bellelli, Valeria Coluccio, Gualtiero Palareti, Marco Marietta, Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Lisa Pieri, Silvia Linari, Francesca Salvianti, Monica Attanasio, Giancarlo Castaman, Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
